Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the...

Descripción completa

Detalles Bibliográficos
Autores: Dohner, H, Wei, AH, Appelbaum, FR, Craddock, C, DiNardo, CD, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Rollig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, JX, Wierzbowska, A, Lowenberg, B
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p15341
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=15341
https://ddd.uab.cat/record/280875
Access Level:acceso abierto
Palabra clave:antineoplastic agent
nucleophosmin
protein bcl 2
acute myeloid leukemia
adult
genetics
human
minimal residual disease
mutation
prognosis
Adult
Antineoplastic Agents
Humans
Leukemia, Myeloid, Acute
Mutation
Neoplasm, Residual
Nucleophosmin
Prognosis
Proto-Oncogene Proteins c-bcl-2
Descripción
Sumario:The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

Similares en LA Referencia